Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trialGerald S. Falchook, Leslie A. Fecher, Nicholas J. Vogelzang et al.|The Lancet Oncology|2012Cited by 541
Predict potential drug targets from the ion channel proteins based on SVMChen Huang, Xia Li, Ruijie Zhang et al.|Journal of Theoretical Biology|2009Cited by 45
Bufalin derivative BF211 inhibits proteasome activity in human lung cancer cells in vitro by inhibiting β1 subunit expression and disrupting proteasome assemblyPeng Sun, Xuan Liu|Acta Pharmacologica Sinica|2016Cited by 23